Vir Biotechnology Inc Cash Flow Conversion Efficiency
Vir Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Vir Biotechnology Inc (VIR) has a cash flow conversion efficiency ratio of 0.126x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($123.33 Million) by net assets ($982.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vir Biotechnology Inc (2017–2025)
Cash flow conversion efficiency of Vir Biotechnology Inc from 2017 to 2025. This chart illustrates how Vir Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Vir Biotechnology Inc stock price today for real-time trading data and today's change.
Vir Biotechnology Inc Cash Flow Conversion Ratio Explained
Vir Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vir Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vir Biotechnology Inc ranked by their cash flow conversion efficiency. Also see Vir Biotechnology Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinhua Winshare Publishing and Media Co Ltd
SHG:601811
|
0.041x |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
-0.073x |
|
China Enterprise Co Ltd
SHG:600675
|
-0.088x |
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
0.022x |
|
EMBOTELL. ANDINA ADR A/6
F:AKOA
|
N/A |
|
Ziff Davis Inc
NASDAQ:ZD
|
0.040x |
|
Primarius Technologies Co. Ltd. A
SHG:688206
|
N/A |
|
Region Group
AU:RGN
|
0.030x |
Annual Cash Flow Conversion Efficiency for Vir Biotechnology Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vir Biotechnology Inc from 2017 to 2025. Review Vir Biotechnology Inc (VIR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $765.28 Million | $-391.78 Million | -0.512x | -31.94% |
| 2024-12-31 | $1.15 Billion | $-446.35 Million | -0.388x | +20.77% |
| 2023-12-31 | $1.59 Billion | $-778.78 Million | -0.490x | -161.18% |
| 2022-12-31 | $2.08 Billion | $1.66 Billion | 0.800x | +2508.30% |
| 2021-12-31 | $1.43 Billion | $-47.59 Million | -0.033x | +87.52% |
| 2020-12-31 | $716.85 Million | $-190.94 Million | -0.266x | +12.89% |
| 2019-12-31 | $423.94 Million | $-129.63 Million | -0.306x | -158.23% |
| 2018-12-31 | $-179.18 Million | $-94.10 Million | 0.525x | -45.48% |
| 2017-12-31 | $-68.92 Million | $-66.38 Million | 0.963x | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more